Compare ABEO & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABEO | IMRX |
|---|---|---|
| Founded | 1974 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 232.9M |
| IPO Year | 1980 | 2021 |
| Metric | ABEO | IMRX |
|---|---|---|
| Price | $5.05 | $7.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $18.20 | $17.20 |
| AVG Volume (30 Days) | ★ 2.8M | 1.2M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.71 | N/A |
| P/E Ratio | $3.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $1.10 |
| 52 Week High | $7.54 | $10.08 |
| Indicator | ABEO | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 65.04 |
| Support Level | $4.37 | $6.62 |
| Resistance Level | $5.17 | $7.62 |
| Average True Range (ATR) | 0.32 | 0.56 |
| MACD | 0.12 | 0.08 |
| Stochastic Oscillator | 65.80 | 94.60 |
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.